FDA data "insufficient for review cost assessment"
This article was originally published in Clinica
Executive Summary
The FDA's report on how much it costs the agency to conduct a product review will not provide the level of detail industry initially wanted. Dr Dale Geiger, the independent contractor conducting the study, told industry last week that the agency's labour reporting system is a truly "blunt tool". It does not differentiate between various types of premarket approval (PMA) applications, whether they be original, product development protocols, modular, expedited or panel-track supplements of Human Device Exemptions.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.